{"nctId":"NCT02302807","briefTitle":"A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]","startDateStruct":{"date":"2015-01-13","type":"ACTUAL"},"conditions":["Bladder Cancer"],"count":931,"armGroups":[{"label":"Arm A: Atezolizumab","type":"EXPERIMENTAL","interventionNames":["Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody"]},{"label":"Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Docetaxel","Drug: Paclitaxel","Drug: Vinflunine"]}],"interventions":[{"name":"Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody","otherNames":["Tecentriq"]},{"name":"Docetaxel","otherNames":[]},{"name":"Paclitaxel","otherNames":[]},{"name":"Vinflunine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically documented locally advanced or metastatic UBC (including renal pelvis, ureters, urinary bladder, and urethra).\n* Representative tumor specimens as specified by the protocol\n* Disease progression during or following treatment with at least one platinum-containing regimen for inoperable, locally advanced or metastatic UBC or disease recurrence\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Life expectancy greater than or equal to (\\>/=) 12 weeks\n* Measurable disease, as defined by RECIST v1.1\n* Adequate hematologic and end organ function\n* For women of childbearing potential, agreement to refrain from heterosexual intercourse or use contraceptive methods that result in a failure rate of \\< 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab, 3 months after the last dose of vinflunine and 6 months from the last dose of paclitaxel or docetaxel.\n* For men, agreement to refrain from heterosexual intercourse or use contraceptive methods that result in a failure rate of \\< 1% per year during the treatment period and for at least 3 months after the last dose of vinflunine and 6 months from the last dose of paclitaxel or docetaxel, and agreement to refrain from donating sperm\n\nExclusion Criteria:\n\n* Any approved anti-cancer therapy within 3 weeks prior to initiation of study treatment\n* Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment\n* Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments\n* Leptomeningeal disease\n* Malignancies other than UBC within 5 years prior to Cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome, or localized prostate cancer treated with curative intent and absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer\n* Pregnant and lactating women\n* Significant cardiovascular disease\n* Severe infections within 4 weeks prior to randomization\n* Major surgical procedure other than for diagnosis within 4 weeks prior to randomization\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins; known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation\n* History of autoimmune disease\n* Prior allogeneic stem cell or solid organ transplant\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan\n* Positive test for human immunodeficiency virus (HIV) and/or active hepatitis B or hepatitis C or tuberculosis\n* Administration of a live, attenuated vaccine within 4 weeks prior to randomization\n* Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, including anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1) or anti-programmed death-ligand 1 (anti-PD-L1) therapeutic antibodies","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS)","description":"OS was defined as time from randomization to death from any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null},{"groupId":"OG001","value":"11.1","spread":null},{"groupId":"OG002","value":"8.2","spread":null},{"groupId":"OG003","value":"8.9","spread":null},{"groupId":"OG004","value":"8.0","spread":null},{"groupId":"OG005","value":"8.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS) as Determined by the Investigator With Use of RECIST v1.1","description":"PFS was defined as the time between the date of randomization and the date of first documented progression of disease (PD) or death, whichever occurred first. PD was determined on the basis of investigator assessment with use of RECIST v1.1. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters had to demonstrate an absolute increase of \\>/= 5 millimeters (mm).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"2.1","spread":null},{"groupId":"OG002","value":"4.2","spread":null},{"groupId":"OG003","value":"2.4","spread":null},{"groupId":"OG004","value":"4.1","spread":null},{"groupId":"OG005","value":"2.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Unconfirmed Duration of Response (DOR) as Determined by the Investigator With Use of RECIST v1.1","description":"DOR was defined as the time from first occurrence of a CR or PR, whichever came first, to first documented PD or death, whichever occurred first. Disease progression was determined on the basis of investigator assessment with use of RECIST v1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \\>/= 5 mm.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"21.7","spread":null},{"groupId":"OG002","value":"6.4","spread":null},{"groupId":"OG003","value":"13.0","spread":null},{"groupId":"OG004","value":"5.5","spread":null},{"groupId":"OG005","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events (AEs)","description":"An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"95.0","spread":null},{"groupId":"OG002","value":"98.2","spread":null},{"groupId":"OG003","value":"96.5","spread":null},{"groupId":"OG004","value":"98.7","spread":null},{"groupId":"OG005","value":"96.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Post-Baseline Anti-therapeutic Antibodies (ATA) to Atezolizumab","description":"Participants were considered post-baseline ATA positive if they had post-baseline ATAs to Atezolizumab that were treatment-induced or treatment-enhanced. Participants had treatment-induced ATAs if they had a baseline-negative ATA result and developed ATAs at any time after initial drug administration. Participants had treatment-enhanced ATAs if they had a baseline-positive ATA result that showed an enhanced signal that was \\>/= 0.60 titer units at any time after initial drug initiation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"35.0","spread":null},{"groupId":"OG002","value":"33.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Minimum Observed Serum Atezolizumab Concentration (Cmin)","description":"Cmin was measured for all participants that received at least one dose of Atezolizumab.","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.5","spread":"29.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.1","spread":"46.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122","spread":"56.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":"72.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":"94.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":"98.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"223","spread":"87.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Unconfirmed Objective Response Rate (ORR) as Determined by the Investigator With Use of Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1)","description":"ORR was defined as the percentage of participants, who had an objective response. Objective response was defined as either a complete response (CR) or partial response (PR) as determined by the investigator with use of Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1). Objective response in this study did not need to be a confirmed response. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. ORR=CR+PR","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"15.4","spread":null},{"groupId":"OG002","value":"29.3","spread":null},{"groupId":"OG003","value":"26.5","spread":null},{"groupId":"OG004","value":"22.2","spread":null},{"groupId":"OG005","value":"16.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Serum Atezolizumab Concentration (Cmax)","description":"Cmax was measured for all participants that received at least one dose of Atezolizumab.","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"334","spread":"125"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score: Global Health Status Scale","description":"The EORTC QLQ-C30 includes five functional scales (physical, role, cognitive, emotional, social); a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms). Key scales included physical functioning, and fatigue, and GHS.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.49","spread":"22.30"},{"groupId":"OG001","value":"64.19","spread":"21.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.47","spread":"20.02"},{"groupId":"OG001","value":"-6.18","spread":"20.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.76","spread":"22.34"},{"groupId":"OG001","value":"-4.67","spread":"20.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.48","spread":"19.71"},{"groupId":"OG001","value":"-0.53","spread":"20.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.95","spread":"24.33"},{"groupId":"OG001","value":"-0.56","spread":"22.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.27","spread":"16.28"},{"groupId":"OG001","value":"1.10","spread":"21.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.67","spread":"7.45"},{"groupId":"OG001","value":"-5.26","spread":"33.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.77","spread":"24.15"},{"groupId":"OG001","value":"-16.71","spread":"24.39"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score: Physical Functioning Scale","description":"The EORTC QLQ-C30 includes five functional scales (physical, role, cognitive, emotional, social); a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms). Key scales included physical functioning, and fatigue, and GHS.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.23","spread":"22.55"},{"groupId":"OG001","value":"76.37","spread":"19.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.80","spread":"15.70"},{"groupId":"OG001","value":"-7.56","spread":"18.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.64","spread":"17.37"},{"groupId":"OG001","value":"-7.06","spread":"19.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.41","spread":"16.25"},{"groupId":"OG001","value":"-3.81","spread":"17.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.97","spread":"20.20"},{"groupId":"OG001","value":"0.89","spread":"16.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.03","spread":"11.30"},{"groupId":"OG001","value":"3.48","spread":"13.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.67","spread":"24.68"},{"groupId":"OG001","value":"3.51","spread":"20.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.58","spread":"25.67"},{"groupId":"OG001","value":"-20.19","spread":"25.52"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score: Fatigue Symptom Scale","description":"The EORTC QLQ-C30 includes five functional scales (physical, role, cognitive, emotional, social); a global health status (GHS)/quality of life (QoL) scale; and items measuring fatigue, pain, nausea and vomiting, dyspnea, appetite loss, sleep disturbance, constipation, diarrhea, and financial difficulties. The score range for each scale and single-item measure is 0 to 100, where higher scores indicate a higher response level (i.e., better functioning, better QoL, worse symptoms). Key scales included physical functioning, and fatigue, and GHS.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.67","spread":"26.66"},{"groupId":"OG001","value":"32.87","spread":"23.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.71","spread":"23.13"},{"groupId":"OG001","value":"10.56","spread":"21.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.04","spread":"25.48"},{"groupId":"OG001","value":"9.41","spread":"24.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.48","spread":"22.63"},{"groupId":"OG001","value":"3.67","spread":"23.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.70","spread":"27.44"},{"groupId":"OG001","value":"-0.95","spread":"23.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"28.97"},{"groupId":"OG001","value":"-8.05","spread":"21.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.56","spread":"16.85"},{"groupId":"OG001","value":"-12.28","spread":"28.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.27","spread":"28.15"},{"groupId":"OG001","value":"19.60","spread":"25.95"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":189,"n":443},"commonTop":["Constipation","Fatigue","Decreased Appetite","Nausea","Anaemia"]}}}